SCHEMBL24424181

SCHEMBL24424181

CON(C)C(=O)c1ncc(F)cc1C(F)(F)F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 1/20 0.38
GPBAR1 Q8TDU6 3/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
MAPT P10636 2/20 0.35
ALDH1A1 P00352 2/20 0.35
TRPM8 Q7Z2W7 1/20 0.35
GRIN2B Q13224 1/20 0.35
RORC P51449 1/20 0.34
PDK2 Q15119 2/20 0.33
GAA P10253 2/20 0.33
ATM Q13315 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
CLK1 P49759 1/20 0.33
DYRK1A Q13627 1/20 0.33
DYRK1B Q9Y463 1/20 0.33
ASPH Q12797 1/20 0.32
HDAC3 O15379 1/20 0.32
HDAC4 P56524 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30133796 1.00 MLYCD (0.38) MLYCDGPBAR1KMT2AMEN1MAPT
SCHEMBL568769 0.82 PDK2 (0.40) MLYCDGPBAR1MAPTTRPM8PDK2
SCHEMBL26468205 0.79 TRPM8 (0.36) MLYCDGPBAR1KMT2AMEN1TRPM8
SCHEMBL30296581 0.79 TRPM8 (0.36) MLYCDGPBAR1KMT2AMEN1TRPM8
SCHEMBL30134388 0.77 ALDH1A1 (0.46) MLYCDKMT2AMEN1MAPTALDH1A1
SCHEMBL30134107 0.77 KIF11 (0.38) KMT2AMEN1MAPTALDH1A1GRIN2B
SCHEMBL23012605 0.75 ASPH (0.46) KMT2AMEN1ALDH1A1GRIN2BASPH
SCHEMBL5654548 0.74 KMT2A (0.51) MLYCDKMT2AMEN1TRPM8ATM
SCHEMBL16468264 0.73 TRPM8 (0.38) MLYCDGPBAR1TRPM8CLK1DYRK1A
SCHEMBL16454316 0.72 MEN1 (0.48) MLYCDGPBAR1KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606541-B2 PPARg modulators and methods of use EISAI R&D MANAGEMENT CO., LTD. (JP) 2026-04-21 US disclosed
CN-116635380-A PPARgamma modulators and methods of use 卫材R&D管理有限公司 2023-08-22 CN disclosed
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-03-02 US disclosed
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-03-02 US disclosed
WO-2022099144-A1 ΡΡΑRγ MODULATORS AND METHODS OF USE Eisai R&D Mangement Co., Ltd. (JP) 2022-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE PPARG, PPARA, PPARD MLYCD 2016/4885GPBAR1 12/4885KMT2A 4267/4885
US-12606541-B2 PPARg modulators and methods of use PPARG, PPARA, PPARD MLYCD 2325/4885GPBAR1 60/4885KMT2A 2698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.